---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-036326"
form_type: "8-K/A"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-08-06T19:45:05+00:00"
generated_at: "2026-08-06T19:46:08.092146+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Ensysce acquires Cy Biopharma and up to $77M private financing for CRPS drug

## Summary
- Acquisition of Cy Biopharma includes clinical-stage neuroplastogenic therapy CY200 for CRPS with FDA Orphan Drug Designation.
- Up to $77M financing: $21.5M initial private placement, $17.1M from Cy Biopharma cash, plus $38.6M milestone tranche.
- Pro forma cash expected to fund CY200 through Phase 2 proof-of-concept and into registrational development.
- James Morrison, Cy Biopharma CEO, becomes President of Ensysce and joins Board of Directors.
- Post-acquisition ownership: Cy Biopharma holders ~74.94%, Ensysce ~7.57%, new investors ~17.49%; combined equity value ~$122.9M.

## SEC filing metadata
- accession: 0001493152-26-036326
- form_type: 8-K/A
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-08-06T19:45:05+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/0001493152-26-036326-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226036326/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-036326
- JSON: https://secwatch.observer/filing/0001493152-26-036326.json
- Plain text: https://secwatch.observer/filing/0001493152-26-036326.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.